Jubilant Life hikes price of Vitamin B3 product by 9 per cent
Jubilant Life Sciences today announced 9 per cent increase in price of its Vitamin B3 product, Niacinamide, with immediate effect. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 12, 2014 Category: Pharmaceuticals Source Type: news

Pioneering Doctors Agree On This …
Almost everyone’s heard of Nobel Prize winner Dr. Linus Pauling. But have you ever heard of Dr. William Kaufman? Dr. Kaufman was a pioneer in the field of curing patients with nutritional therapy. He was the first to use high doses of vitamin B3 to treat arthritis sufferers. He passed away in the year 2000 [...]Related Posts:Aging and EnergyStone Age Energy (Source: Al Sears, MD Natural Remedies)
Source: Al Sears, MD Natural Remedies - June 3, 2014 Category: Complementary Medicine Authors: Cathy Card Tags: Newsletter Source Type: news

Daily vitamin B3 intake could help treat degenerative childhood disease
(NaturalNews) Vitamin B3 may be a miracle treatment for the genetic childhood disease Friedreich's ataxia -- which currently has no treatment or cure -- according to a study conducted by researchers from Imperial College London, University College London and the National Institute... (Source: NaturalNews.com)
Source: NaturalNews.com - May 22, 2014 Category: Consumer Health News Source Type: news

Make the diagnosis, Sherlock!
This is a case recently reported in the Medical Journal of Australia.  A 50-year-old woman presented with a read, painful, scaling rash on her hand an forearms, and around her eyes. She reported that sun exposure aggravated the dermal symptoms. She also gave a history of intermittent diarrhea. Examination revealed a scaly hyperpigmented lesion on her upper chest, in the distribution of a broad collar. The patient was a smoker and said she consumed half a bottle of gin daily. The skin manifestations did not respond to antibiotics or steroids. Click on the following questions to reveal the answers. Was is the diagn...
Source: The Poison Review - May 22, 2014 Category: Toxicology Authors: Leon Tags: Medical dermatitis niacin deficiency pellagra Source Type: news

Vitamin B3 might have been made in space, delivered to Earth by meteorites
Ancient Earth might have had an extraterrestrial supply of vitamin B3 delivered by carbon-rich meteorites, according to a new analysis. The result supports a theory that the origin of life may have been assisted by a supply of key molecules created in space and brought to Earth by comet and meteor impacts. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 18, 2014 Category: Science Source Type: news

Energizing sick mitochondria with vitamin B3: Effective treatment for mitochondrial disease
Vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases, new research suggests. Vitamins B have recently been turned out to be potent modifiers of energy metabolism, especially the function of mitochondria. Vitamin B3, (niacin) has been found to delay the signs of aging in animal models. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2014 Category: Science Source Type: news

Energizing sick mitochondria with vitamin B3
(University of Helsinki) The researchers of the University of Helsinki, Finland, and École Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 7, 2014 Category: Biology Source Type: news

Jubilant Life to hike Niacin prices by 18%
Drug-maker Jubilant Life Sciences today announced a price increase of 18 per cent for Niacin feed-grade, with immediate effect. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 13, 2014 Category: Pharmaceuticals Source Type: news

Could niacin be the fountain of youth?
The vitamin niacin has a life-prolonging effect, as Michael Ristow has demonstrated in roundworms. From his study, the ETH-Zurich professor also concludes that so-called reactive oxygen species are healthy, not only disagreeing with the general consensus, but also many of his peers. Who would not want to live a long and healthy life? A freely available food supplement could help in this respect, scientists from ETH Zurich have demonstrated in roundworms... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2013 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Niacin, the fountain of youth
(ETH Zurich) The vitamin niacin has a life-prolonging effect, as Michael Ristow has demonstrated in roundworms. From his study, the ETH-Zurich professor also concludes that so-called reactive oxygen species are healthy, not only disagreeing with the general consensus, but also many of his peers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 30, 2013 Category: Global & Universal Source Type: news

Nutrition 101: Niacin
(HealthCastle.com) Niacin, also known as vitamin B3, is one of 8 B vitamins.  All of the B vitamins are water-soluble, meaning that the body does not store them but excretes them in the urine. Other names for niacin include nicotinic acid and nicotinamide / niacinamide.  read more (Source: HealthCastle.com Nutrition Tips - written by Registered Dietitians)
Source: HealthCastle.com Nutrition Tips - written by Registered Dietitians - September 8, 2013 Category: Nutrition Source Type: news

Adding Niacin to Statins Improves HDL Levels, Not HDL FunctionAdding Niacin to Statins Improves HDL Levels, Not HDL Function
Raising HDL cholesterol levels by adding niacin to statins doesn't improve clinical outcomes, and a new letter in the Journal of the American College of Cardiology suggests why that might be the case. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Adding Niacin No Help for HDL Function (CME/CE)
(MedPage Today) -- Despite increasing HDL cholesterol levels, the addition of niacin (Niaspan) to statin therapy did not improve the beneficial functions of HDL cholesterol, which could explain the drug's failure to improve clinical outcomes in recent large clinical trials, researchers found. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 8, 2013 Category: Consumer Health News Source Type: news

Cardio Notes: Niacin and Stroke Risk
(MedPage Today) -- The correlation of niacin with stroke in the AIM-HIGH trial lost significance when other factors were considered. Also this week, finding vulnerable coronary lesions before they rupture and improving fluoro time. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 29, 2013 Category: Cardiology Source Type: news

Potential for new therapeutic options for a diverse array of challenging medical disorders
Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases - a diverse set of difficult-to-treat genetic-based energy disorders. Using that knowledge, they showed that nicotinic acid, a form of vitamin B3, partially restores normal functioning in cells taken from patients with mitochondrial disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 26, 2013 Category: Consumer Health News Tags: Public Health Source Type: news

In A Mouse Model Of Polycystic Kidney Disease, Vitamin B3 Blocks Cyst Formation
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited systemic disorder caused by mutations in PKD1 or PKD2 that predominately affects the kidneys and is characterized by the formation of cysts in the kidneys and other organs. Xiaogang Li and colleagues at the University of Kansas Medical Centr used a mouse model of ADPKD to explore the role of the protein sirtuin 1 in cyst formation. They found that inhibition of sirtuin 1 activity using vitamin B3 can reduced cyst formation in the kidneys of ADPKD mice... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 19, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Vitamin B3 fights superbug infections naturally: Study
As researchers continue the hunt for ways to stem the growing threat of the lethal superbug MRSA (Methicillin-resistant Staphylococcus aureus), one safe and easy remedy may be going overlooked: Vitamin B3, also known as niacin. S. aureus is a natural part of healthy... (Source: NaturalNews.com)
Source: NaturalNews.com - June 13, 2013 Category: Consumer Health News Source Type: news

Increased Niacin (Niaspan) Use in US, CanadaIncreased Niacin (Niaspan) Use in US, Canada
Nearly 700 000 prescriptions per month were written in the US at the end of 2009, an increase of 191% from 2002. In Canada, the use of niacin increased sevenfold, with nearly 14 000 prescriptions written at the end of 2009. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Niacin use increased nearly 200% over seven-year period
Nearly 700 000 prescriptions per month were written in the US at the end of 2009, an increase of 191% from 2002. In Canada, the use of niacin increased sevenfold, with nearly 14 000 prescriptions written at the end of 2009. (Source: theHeart.org)
Source: theHeart.org - June 10, 2013 Category: Cardiology Source Type: news

HPS2-THRIVE Trial of ER Niacin/LaropiprantHPS2-THRIVE Trial of ER Niacin/Laropiprant
Will extended release niacin be a help or hindrance to adherence and tolerability factors -- when added to lipid lowering regimens? European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Forum: Niacin and Depression?
Bellaclarke recently posted on the forum: Hi, I've been treated for depression for 12 years with various different antidepressants. At best, they make me feel numb. Also, I experienced side effects from every single type I've taken.  I've reached my breaking point and don't feel like antidepressants are the answer any more.  I've recently done a significant amount of research into high doses of niacin as an alternative to traditional pills. This week I started taking 1000mg of non-flush niacin. Has anyone on here every taken it? What doses did you take? Did it work? Did you take flush or non-flush niacin?......
Source: About.com Depression - April 22, 2013 Category: Psychiatry Source Type: news

Niacin (Niaspan) adverse events in AIM-HIGH, HPS2-THRIVENiacin (Niaspan) adverse events in AIM-HIGH, HPS2-THRIVE
AIM-HIGH researchers have yet to publish a detailed post hoc analysis of adverse events related to niacin therapy, but the investigators do not believe there was a real risk of bleeding or infection observaed with the proprietary extended-release niacin in the trial. However, the HPS2-THRIVE team believes the results of AIM-HIGH support their conclusions about niacin's off-target risks. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Niacin adverse events disputed in AIM-HIGH and HPS2-THRIVE
AIM-HIGH researchers have yet to publish a detailed post hoc analysis of adverse events related to niacin therapy, but the investigators do not believe there was a real risk of bleeding or infection observed with the proprietary extended-release niacin in the trial. However, the HPS2-THRIVE team believes the results of AIM-HIGH support their conclusions about niacin's off-target risks. (Source: theHeart.org)
Source: theHeart.org - March 26, 2013 Category: Cardiology Source Type: news

Niacin And Laropiprant Combo Shows No Benefits, Has Some Harmful Effects In Patients With Vascular Disease
A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2013 Category: Consumer Health News Tags: Vascular Source Type: news

Conference report: Niacin/laropripant combination (Tredaptive) associated with increased risk of bleeding and infections
Source: Reuters Health News Area: News Reuters Health News has reported that according to data presented at the annual American College of Cardiology scientific meeting, niacin in combination with laropripant (Tredaptive) was associated with statistically significantly higher rates of bleeding (2.5% vs 1.9%), and infections (8.0% vs 6.6%) compared to patients taking simvastatin or simvastatin/ezetimibe. They called the differences unexpected.   Additionally, patients taking Tredaptive also experienced higher rates of serious health problems that researchers said are known side effects of niacin, which included ne...
Source: NeLM - Cardiovascular Medicine - March 12, 2013 Category: Cardiology Source Type: news

Merck's Long-Acting Niacin Drug Has Serious Side Effects
Tredaptive, Merck & Co's long-acting niacin medication aimed at elevating HDL cholesterol (good cholesterol) has unexpected serious side effects, researchers announced on Saturday. This is more evidence against using niacin therapy for heart patients. A major study (HPS2-THRIVE) found that Tredaptive, which consist of the vitamin niacin combined with anti-flushing agent laropiprant, provides no benefit and may even be hazardous for patients with vascular disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Niacin Won't Help, May Harm Heart Patients: Study
Title: Niacin Won't Help, May Harm Heart Patients: StudyCategory: Health NewsCreated: 3/9/2013 2:35:00 PMLast Editorial Review: 3/11/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 11, 2013 Category: Cardiology Source Type: news

"If not dead, not healthy": Niacin full results in HPS2-THRIVE aired at ACC
Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, with approximately 30 adverse events per 1000 treated patients. (Source: theHeart.org)
Source: theHeart.org - March 10, 2013 Category: Cardiology Source Type: news

Big Bucks, No Benefits with Many Drugs
(MedPage Today) -- Cardiologists meeting in San Francisco were told that extended-release niacin has no measurable benefits in heart disease and many risks. But niacin is not the only popular treatment that piles up profits without proof. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 10, 2013 Category: Cardiology Source Type: news

Niacin Full Results in HPS2-THRIVE Aired at ACCNiacin Full Results in HPS2-THRIVE Aired at ACC
Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, w Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

ACC: HPS2-THRIVE May Signal the End for Niacin (CME/CE)
SAN FRANCISCO (MedPage Today) -- Results from a landmark study of specially formulated niacin in more than 25,000 high-risk patients appears to have extinguished any clinical role for niacin to reduce the risk of cardiovascular events in these patients, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 9, 2013 Category: Cardiology Source Type: news

Serious side effects seen with failed Merck niacin drug
SAN FRANCISCO (Reuters) - Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients. (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
Dateline City:  SAN FRANCISCO SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE™(extended-release niacin/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62nd Annual Scientific Sessions (abstract 300-14). Language: ...
Source: Merck.com - Research and Development News - March 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news

ACC: Eyes Are on Watchman, Niacin
SAN FRANCISCO (MedPage Today) -- The Watchman left atrial appendage closure device and details from a failed niacin trial will be in the spotlight when the American College of Cardiology meeting kicks off Saturday. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 7, 2013 Category: Cardiology Source Type: news

Niacin-statin combo tied to skin, muscle side effects
NEW YORK (Reuters Health) - One-quarter of people taking niacin and statins as part of a four-year-long heart study dropped out early, often for medical reasons tied to niacin's side effects, a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Niacin-Statin Combo Tied to Skin, Muscle Side Effects
One-quarter of people taking niacin and statins as part of a four-year-long heart study dropped out early, often for medical reasons tied to niacin's side effects, a new study suggests.Source: Reuters Health Related MedlinePlus Pages: B Vitamins, Cholesterol, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 27, 2013 Category: Consumer Health News Source Type: news

Side Effects Dim Niacin Promise (CME/CE)
(MedPage Today) -- A highly significant increase in adverse events, in particular myopathy, appears to have been a driving force behind the decision to shut down a pivotal trial of Tredaptive, the agent that many hoped would improve niacin tolerance. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 27, 2013 Category: Cardiology Source Type: news

Niacin Adverse Events in HPS2-THRIVENiacin Adverse Events in HPS2-THRIVE
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Niacin-Statin Combo May Cause Side Effects for Heart Patients
Title: Niacin-Statin Combo May Cause Side Effects for Heart PatientsCategory: Health NewsCreated: 2/26/2013 8:35:00 PMLast Editorial Review: 2/27/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 27, 2013 Category: Cardiology Source Type: news

Coming Attraction: First Look At What Went Wrong With Niacin
In a few weeks, on March 9, the main results of the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study will be presented in San Francisco at the annual meeting of the American College of Cardiology. These results have been eagerly awaited since Merck's brief announcement in December that the trial had not met its primary endpoint and that it would no longer pursue approval of Tredaptive, the combination of extended-release niacin and laropiprant, in the US. The trial was designed to assess whether adding t...
Source: Forbes.com Healthcare News - February 27, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

HPS2-THRIVE: High myopathy risk with niacin/laropiprant
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. (Source: theHeart.org)
Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news

MHRA Drug Safety Update: TredaptiveT (niacin-laropiprant) no longer recommended for prescribing
Source: MHRA Area: News The January issue of the MHRA's Drug Safety Update has featured new data from a long-term study (HPS2-THRIVE) involving over 25 000 patients which indicated that adding TredaptiveT (fixed dose niacin-laropiprant) to simvastatin did not provide significant additional benefit in reducing the risk of major vascular events compared with statin therapy alone. In addition, a higher frequency of bleeding (intracranial and gastro-intestinal), myopathy, infections and new-onset diabetes was seen in patients taking Tredaptive with simvastatin, compared with patients taking simvastatin alone.   In li...
Source: NeLM - Cardiovascular Medicine - January 30, 2013 Category: Cardiology Source Type: news

Trials Of Niacin And Atrial Fibrillation Device Will Headline American College Of Cardiology Program
Two big trials will highlight this year's American College of Cardiology meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific's long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation. Second is  the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The final list of trials has been posted on the ACC website. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 22, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Niacin/Laropiprant Products to Be Withdrawn in EU Next WeekNiacin/Laropiprant Products to Be Withdrawn in EU Next Week
The Committee for the Medicinal Products of Human Use of the European Medicines Agency has followed the advice of its pharmacovigilance risk assessment team and confirmed it will recommend suspension of niacin/laropiprant products. Doctors should no longer prescribe the agents, which will cease to be available in the EU as of next week. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2013 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Niacin/laropiprant products to be withdrawn in EU next week
The Committee for the Medicinal Products of Human Use of the European Medicines Agency has followed the advice of its pharmacovigilance risk assessment team and confirmed it will recommend suspension of niacin/laropiprant products. Doctors should no longer prescribe the agents, which will cease to be available in the EU as of next week. (Source: theHeart.org)
Source: theHeart.org - January 18, 2013 Category: Cardiology Source Type: news

Niacin/laropiprant products to be suspended worldwide
The European Medicines Agency (EMA) has recommended that the marketing, supply, and authorisations of three identical niacin/laropiprant products—Tredaptive, Pelzont, and Trevaclyn—for the treatment of adults with dyslipidemia be suspended across the European Union (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 15, 2013 Category: Drugs & Pharmacology Source Type: news

PRAC recommends suspension of marketing authorisations of extended-release niacin/laropiprant (Tredaptive®) across the EU
Source: European Medicines Agency Area: News The European Medicines Agency (EMA)'s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that the marketing, supply and authorisations of extended-release niacin/laropiprant medicines (Tredaptive®) be suspended across the EU. This follows an assessment of the available data related to safety concerns, and the conclusion by the Committee that the risks are greater than the benefits in adults with dyslipidaemia. For further details, please see a related Q&A document at the link below.   The EMA recently advised that no new patients be started on ...
Source: NeLM - Cardiovascular Medicine - January 14, 2013 Category: Cardiology Source Type: news

What Merck Told Doctors About Tredaptive Before It Stopped Selling It
This morning, Merck announced that it would suspend sales of Tredaptive, the heart drug that combines the B vitamin niacin with a new medicine, laropiprant, that prevents niacin's main side effect, hot, unpleasant, facial flushing. This comes just weeks after a big trial of Tredaptive not only found that the drug did not prevent heart attacks, strokes, and heart procedures as was expected bu that it also caused many serious side effects. The European Medicines Agency also issued a review saying that Tredaptive's benefits do not outweigh its risks. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 11, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Merck Pulls Niacin Drug
(MedPage Today) -- Merck is suspending worldwide availability of its niacin drug Tredaptive, after the European Medicines Agency recommended it no longer be marketed in Europe. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 11, 2013 Category: Cardiology Source Type: news

Niacin/Laropiprant Products to Be Suspended WorldwideNiacin/Laropiprant Products to Be Suspended Worldwide
The European's Medicines Agency is likely the first of many to propose the suspension of niacin/laropiprant products for dyslipidemia following the failure of the HPS-2 THRIVE trial; Merck confirms it will suspend availability of the medicine where it is available. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 11, 2013 Category: Cardiology Tags: Cardiology News Alert Source Type: news